NasdaqGS:BMRN

Stock Analysis Report

Executive Summary

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has BioMarin Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

NasdaqGS:BMRN

0.6%

US Biotechs

1.3%

US Market


1 Year Return

-26.9%

NasdaqGS:BMRN

-10.3%

US Biotechs

2.0%

US Market

BMRN underperformed the Biotechs industry which returned -10.8% over the past year.

BMRN underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

BMRNIndustryMarket
7 Day0.7%0.6%1.3%
30 Day-5.0%-1.2%3.9%
90 Day-13.7%-0.1%3.4%
1 Year-26.9%-26.9%-9.5%-10.3%4.2%2.0%
3 Year-25.0%-25.0%7.1%3.5%47.2%37.6%
5 Year4.0%4.0%3.3%-1.7%60.5%42.9%

Price Volatility Vs. Market

How volatile is BioMarin Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioMarin Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

33%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BioMarin Pharmaceutical's share price is below the future cash flow value, and at a moderate discount (> 20%).

BioMarin Pharmaceutical's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

BioMarin Pharmaceutical is loss making, we can't compare its value to the US Biotechs industry average.

BioMarin Pharmaceutical is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BioMarin Pharmaceutical, we can't assess if its growth is good value.


Price Based on Value of Assets

BioMarin Pharmaceutical is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is BioMarin Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 22 analysts?

74.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioMarin Pharmaceutical's revenue is expected to grow by 17.7% yearly, however this is not considered high growth (20% yearly).

BioMarin Pharmaceutical's earnings are expected to grow significantly at over 20% yearly.

BioMarin Pharmaceutical's revenue growth is expected to exceed the United States of America market average.

BioMarin Pharmaceutical's earnings growth is expected to exceed the United States of America market average.

BioMarin Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

BioMarin Pharmaceutical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has BioMarin Pharmaceutical performed over the past 5 years?

9.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioMarin Pharmaceutical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare BioMarin Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BioMarin Pharmaceutical's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BioMarin Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if BioMarin Pharmaceutical has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BioMarin Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BioMarin Pharmaceutical's financial position?


Financial Position Analysis

BioMarin Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioMarin Pharmaceutical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioMarin Pharmaceutical's level of debt (28.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (44.5% vs 28.3% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BioMarin Pharmaceutical has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if BioMarin Pharmaceutical has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is BioMarin Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioMarin Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioMarin Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioMarin Pharmaceutical has not reported any payouts.

Unable to verify if BioMarin Pharmaceutical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioMarin Pharmaceutical has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of BioMarin Pharmaceutical's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of BioMarin Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

8.5yrs

Average management tenure


CEO

Jean-Jacques Bienaimé (66yo)

14.3yrs

Tenure

US$15,627,893

Compensation

Mr. Jean-Jacques Bienaime, MBA, has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Director at Vital Therapies, Inc. since September 2013 to October 10, 2018 ...


CEO Compensation Analysis

Jean-Jacques's remuneration is higher than average for companies of similar size in United States of America.

Jean-Jacques's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

8.5yrs

Average Tenure

60yo

Average Age

The average tenure for the BioMarin Pharmaceutical management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.9yrs

Average Tenure

66yo

Average Age

The tenure for the BioMarin Pharmaceutical board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Dan Spiegelman (60yo)

    Executive VP & CFO

    • Tenure: 0yrs
    • Compensation: US$4.52m
  • Jean-Jacques Bienaimé (66yo)

    Chairman & CEO

    • Tenure: 14.3yrs
    • Compensation: US$15.63m
  • Robert Baffi (64yo)

    President of Global Manufacturing & Technical Operations

    • Tenure: 0yrs
    • Compensation: US$4.43m
  • Hank Fuchs (61yo)

    President of Worldwide Research & Development

    • Tenure: 2.9yrs
    • Compensation: US$5.78m
  • George Davis (48yo)

    Executive VP

    • Tenure: 15.7yrs
    • Compensation: US$2.71m
  • Jeff Ajer (57yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 6.9yrs
    • Compensation: US$4.55m
  • Brian Mueller (45yo)

    Senior VP of Finance & Chief Accounting Officer

    • Tenure: 8.5yrs
  • Traci McCarty

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Philip Scalzo

    Senior VP & Chief Compliance Officer

    • Tenure: 0yrs
  • Lon Cardon

    Senior VP & Chief Scientific Officer

    • Tenure: 0yrs

Board Members

  • Randy Meier (59yo)

    Lead Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$544.66k
  • Jean-Jacques Bienaimé (66yo)

    Chairman & CEO

    • Tenure: 14.3yrs
    • Compensation: US$15.63m
  • Mike Grey (66yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$489.91k
  • David E. Pyott (66yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: US$479.91k
  • Elaine Heron (71yo)

    Independent Director

    • Tenure: 17.2yrs
    • Compensation: US$500.66k
  • Alan Lewis (73yo)

    Independent Director

    • Tenure: 14.3yrs
    • Compensation: US$489.91k
  • V. Lawlis (67yo)

    Independent Director

    • Tenure: 12.3yrs
    • Compensation: US$481.91k
  • Will Dere (65yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$478.66k
  • Dennis Slamon (70yo)

    Independent Director

    • Tenure: 5.5yrs
    • Compensation: US$478.66k
  • Bob Hombach (53yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$492.91k

Company Information

BioMarin Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioMarin Pharmaceutical Inc.
  • Ticker: BMRN
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$13.038b
  • Shares outstanding: 179.46m
  • Website: https://www.biomarin.com

Number of Employees


Location

  • BioMarin Pharmaceutical Inc.
  • 770 Lindaro Street
  • San Rafael
  • California
  • 94901
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMRNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 1999
BM8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 1999
BMRNWBAG (Wiener Boerse AG)YesCommon StockATEURJul 1999
0HNCLSE (London Stock Exchange)YesCommon StockGBUSDJul 1999
BMRN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 1999

Biography

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products inclu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 23:33
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.